2. A monitored prescription drug is compounded, packaged, or labeled in preparation for delivery but is not delivered.
3. The prescription order is for a monitored prescription drug that is a substance listed in the schedule in s. 961.22 and is not a narcotic drug, and the prescription order is for a number of doses that is intended to last the patient 7 days or less. (b) Identify specific data elements to be contained in a record documenting the dispensing of a monitored prescription drug, including the method of payment and, subject to sub. (2m), the name recorded under s. 450.11 (1b) (bm). In identifying specific data elements, the board shall consider data elements identified by similar programs in other states and shall ensure, to the extent possible, that records generated by the program are easily shared with other states. (c) Specify the persons to whom a record may be disclosed and the circumstances under which the disclosure may occur. Except as otherwise provided under this section, the rule promulgated under this paragraph shall comply with s. 146.82. (cm) Permit the board to disclose a record generated by the program to any of the following:
1. A practitioner, pharmacist, registered nurse licensed under s. 441.06, substance abuse counselor, as defined in s. 440.88 (1) (b), or individual authorized under s. 457.02 (5m) to treat alcohol or substance dependency or abuse as a specialty if any of the following is applicable: a. The practitioner, pharmacist, registered nurse, substance abuse counselor, or individual is directly treating or rendering assistance to the patient.
b. The practitioner, pharmacist, registered nurse, substance abuse counselor, or individual is being consulted regarding the health of the patient by an individual who is directly treating or rendering assistance to the patient.
2. A person who medically coordinates, directs, or supervises, or establishes standard operating procedures for, a practitioner, pharmacist, registered nurse, substance abuse counselor, or individual authorized under s. 457.02 (5m) to treat alcohol or substance dependency or abuse as a specialty to whom records may be disclosed under subd. 1., if the person is evaluating the job performance of the practitioner, pharmacist, registered nurse, substance abuse counselor, or individual, or is performing quality assessment and improvement activities, including outcomes evaluation or development of clinical guidelines, and if the disclosure does not contain personally identifiable information, as defined in s. 19.62 (5), of a patient and is limited to only those records about the practitioner, pharmacist, registered nurse, substance abuse counselor, or individual the person medically coordinates, directs, or supervises, or for whom the person establishes standard operating procedures. 3. Relevant state boards and agencies, relevant agencies of other states, relevant law enforcement agencies, as defined in s. 165.77 (1) (b), and relevant prosecutorial units, as defined in s. 978.001 (2), if any of the following is true: a. The state board or agency, agency of another state, law enforcement agency, or prosecutorial unit makes a written request for the record and is engaged in an active and specific investigation or prosecution of a violation of any state or federal law involving a monitored prescription drug, and the record being requested is reasonably related to that investigation or prosecution.
b. The state board or agency, agency of another state, law enforcement agency, or prosecutorial unit makes a written request for the record and is monitoring the patient as part of a drug court, as defined in s. 165.955 (1). c. The circumstances indicate suspicious or critically dangerous conduct or practices of a pharmacy, pharmacist, practitioner, or patient. The board shall define what constitutes suspicious or critically dangerous conduct or practices for purposes of this subd. 3. c.
4. An agent of a practitioner or pharmacist if disclosure to the practitioner or pharmacist is authorized subject to subd. 1.
(cs) 1. Require a practitioner to review a patient’s records under the program before the practitioner issues a prescription order for the patient. This subdivision does not apply after April 1, 2020 or 3 years after the 30th day after the date of publication in the Wisconsin Administrative Register of the notice under 2015 Wisconsin Act 266, section 17 (2g), whichever is later. 2. The requirement under subd. 1. that a practitioner review a patient’s records under the program before the practitioner issues a prescription order for the patient does not apply if any of the following is true:
a. The patient is receiving hospice care, as defined in s. 50.94 (1) (a). b. The prescription order is for a number of doses that is intended to last the patient 3 days or less and is not subject to refill.
c. The monitored prescription drug is lawfully administered to the patient.
d. Due to emergency, it is not possible for the practitioner to review the patient’s records under the program before the practitioner issues a prescription order for the patient.
e. The practitioner is unable to review the patient’s records under the program because the digital platform for the program is not operational or due to other technological failure if the practitioner reports that failure to the board.
(d) Specify a secure electronic format for submittal of a record generated under the program and authorize the board to grant a pharmacy or practitioner a waiver of the specified format.
(e) Specify a deadline for the submittal of a record to the board.
(f) Permit the board to refer to the appropriate licensing or regulatory board for discipline, or the appropriate law enforcement agency for investigation and possible prosecution, a pharmacist, pharmacy, or practitioner that fails to comply with rules promulgated under this subsection, including by failure to generate a record that is required by the program.
(g) Maximize the potential for funding the operation of the program with available federal funding sources.
(h) Ensure that the program complies with s. 146.82, except as otherwise provided in this section, and 45 CFR part 164, subpart E. (i) Disclose information submitted to the program by a law enforcement agency under s. 961.37 (3) (a) to relevant practitioners, pharmacists, and others to whom the board may make disclosures under par. (c). Related statute or rule: N/A
Plain language analysis:
Section 1 updates the authority and scope to reflect the disclosure of information and the dispensing of monitored prescription drugs.
Section 2 updates the definition of “access” to reflect the ability to view monitored prescription drug history reports, audit trails and PDMP data. The definition of administer is updated to reflect the new statutory definition.
Section 3 creates new definitions for “agent”, “audit trail”, “business day” and “deliver or delivery”. “Agent”, “business day” and “deliver or delivery” have the same definitions as the statutes. “Audit trail” is a log of each time the PDMP system discloses information and the type of information disclosed.
Section 4 updates the statutory reference in the definition of “dispense”.
Section 5 creates definitions of “healthcare professional”, which is a pharmacist, practitioner, registered nurse, substance abuse counselor or an individual credentialed by the Marriage and Family Therapy, Professional Counseling and Social Work Examining Board with the substance use disorder specialty, and “law enforcement agency” which has the meaning given in statutes.
Section 6 amends the definition of “managing pharmacist” as a pharmacist who has responsibility and direct control of the pharmaceutical operations in a pharmacy.
Section 7 creates definitions for “medical coordinator” and “monitored prescription drug history report”. A medical coordinator is the person responsible for the operating procedures for a healthcare professional. Monitored prescription drug history report includes the PDMP data, required reports, information submitted to the program and the information form the analytics platform.
Section 8 updates the statutory reference in the patient definition.
Section 9 repeals the definition for person authorized by the patient.
Section 10 updates the definition of “PDMP data” as the information compiled and analyzed by the system based upon data submitted by dispensers.
Section 11 repeals the portion of the “PDMP information” definition because it no longer is applicable.
Section 12 creates definitions for “PDMP system” and “personally identifiable information”. The PDMP system is the entire hardware and software of the systems. Personally identifiable information is information which identifies a person.
Section 13 updates the definitions of “pharmacist”, “pharmacist delegate”, “pharmacy”, “practitioner” and “practitioner delegate”. “Pharmacist” is updated to recognize pharmacists who are licensed in another state but engage in practice in Wisconsin or at a pharmacy licensed as an out-of-state pharmacy. “Pharmacist delegate” and “practitioner delegate” are updated to reflect the change in terminology from PDMP information to monitored prescription drug history reports. The “pharmacy” definition has an updated statutory reference. “Practitioner” definition adds people who are licensed in another state but can legally engage in practice in our state without a Wisconsin license.
Section 14 creates a definition of “prescribing metrics report” which includes PDMP data, audit trails, reports about a patient submitted to the program and information from the analytics platform. It also creates a definition for “prosecutorial unit” citing the definition in statute.
Section 15 repeals from the drugs that have a substantial potential for abuse, those substances which are identified in schedule IV or V in the Wisconsin controlled substances schedules due to these substances are monitored drugs and no longer need the separate identification.
Section 16 repeals the definitions for “dispenser identifier”, “NPI number” and “practitioner identifier” as they are no longer utilized.
Section 17 removes dispenser identifier and practitioner identifier and replaces with the DEA registration number; removes the name and strength of the monitored prescription drug. It also clarifies the language that the board may refer a dispenser and dispenser delegate for failing to comply the dispensing data to the appropriate licensing board for discipline.
Section 18 updates that dispensing data may be transmitted in multiple ways.
Section 19 creates that dispensing data may be submitted as a file that complies with the data standards identified in the implementation guide. Or by using the prescription record entry functions of the system.
Section 20 recreates the note for how the data standards in version 4 release 2 of the ASAP implementation guide for prescription monitoring programs may be obtained.
Section 21 repeals two portions of electronic submission of dispensing data which are no longer methods of submission.
Section 22 indicates that the board may refer a dispenser or delegate that fail to submit data to the licensing board for discipline.
Section 23 requires submission of dispensing data to the PDMP no later than 11:59 p.m. the next business day after the monitored prescription drug is dispensed. If no monitored prescription drug is dispensed during that business day, the dispenser shall submit a zero report. If a report is unable to be submitted due to circumstances beyond the control of the dispenser, the dispenser may request an emergency waiver from the board. The board may refer a dispenser or delegate that fail to submit data to the licensing board for discipline.
Section 24 creates provisions for correcting dispensing data within 5 business days of discovering the error. The board may refer a dispenser or delegate that fails to correct data to the licensing board for discipline or to law enforcement for possible prosecution.
Section 25 creates a provision that a dispenser is not required to submit dispensing data when a drug is prepared for delivery but not yet delivered.
Section 26 repeals and recreates the provisions relating to access to monitored prescription drug history reports and PDMP data to reflect updated terminology and requirements as a result of Acts 266, 267 and 268. Monitored prescription drug history reports may be accessed by healthcare professionals, pharmacists and pharmacist delegates if the individual is treating or rendering assistance to the patient or the individual is being consulted regarding the health of the patient. Healthcare professionals, pharmacists and pharmacist delegates may only disclose monitored prescription drug history reports to the patient, to another healthcare professional or medical coordinator for consultation, to the pharmacist or practitioner who is directly treating or rendering assistance or to a law enforcement agency.
Section 27 creates a section regarding monitored prescription drug history reports and audit trails about healthcare professions. Healthcare professionals may access audit trails about themselves and their delegates. A practitioner may access the audit trails accessible to healthcare professionals and a prescribing metrics report about themselves. Medical coordinators may access prescribing metrics reports and audit trails about individuals they direct or supervise or if they are evaluating the job performance or performing quality assessment and improvement activities.
Section 28 provides grounds for denying, suspending, revoking or restricting or limiting access to the PDMP.
